Brauchli YB, Jick SS, Miret M, Meier CR Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol. 2009 May;160(5):1048-56. doi: 10.1111/j.1365-2133.2008.09020.x. Epub 2009 Feb 4.
Kaye JA, Li L, Jick SS Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008 Sep;159(4):895-902. doi: 10.1111/j.1365-2133.2008.08707.x. Epub 2008 Jul 4.
Lindegard B Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica. 1986;172(6):298-304. doi: 10.1159/000249365.
Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010 Apr;31(8):1000-6. doi: 10.1093/eurheartj/ehp567. Epub 2009 Dec 27.
Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Schnohr P, Jensen JS Tissue Doppler echocardiography in persons with hypertension, diabetes, or ischaemic heart disease: the Copenhagen City Heart Study. Eur Heart J. 2009 Mar;30(6):731-9. doi: 10.1093/eurheartj/ehn596. Epub 2009 Jan 27.
Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006 Dec;298(7):321-8. doi: 10.1007/s00403-006-0703-z. Epub 2006 Sep 22.
Wu Y, Mills D, Bala M Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol. 2008 Apr;7(4):373-7.
Xiao J, Chen LH, Tu YT, Deng XH, Tao J Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1311-5. doi: 10.1111/j.1468-3083.2009.03318.x. Epub 2009 Jun 1.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
